Lung Cancer MCN Work Plan 2017/18

Transcription

1 Lung Cancer MCN Work Plan /18 Objective Deliverables / Outcomes Lead 1. Manage the development/review of Lung Cancer Management Guidelines Regional Management Guidelines circulated for implementation. MCN 1.1 Identify lead author/reviewer and communicate requirements of the development/review process in accordance with WoSCAN Standard Operating Procedures. Timely and consistent development/ review of Clinical Management Guidelines and Clinical Guidance Documents in accordance with WoSCAN Standard Operating Procedures. Clinical Management Guidelines: Mesothelioma Small Cell Lung Cancer Non Small Cell Lung Cancer 2. Participation in the West of Scotland rolling programme of regional and national education events; utilising the opportunity for learning and sharing of current best practice and innovation. Established Managed Clinical Network educational events maximised to promote best practice and drive improvement in care delivery. MCN / Clinician(s) TBC MCN / Clinicians(S) TBC MCN / Clinician(s) TBC Lead MCN 2.1 Contribute to programme development for the national Scottish Lung Cancer Forum meeting. Tripartite agreement of national programme across Networks. Lead MCN Oct Lung Cancer MCN Work Plan /18 v1.0 25/04/ 1

2 3. Support delivery of the National Cancer Quality Programme for /18, ensuring the regional/national governance process is adhered to. 3.1 Support the data verification process as defined by regional/local governance framework. Programme delivered in line with agreed download schedule, Quality Performance Indicators (QPIs) and governance processes. Clinical and service issues are escalated and actioned appropriately. Audit data reports verified by NHS Boards. Board comments returned for inclusion in annual Audit Reports. Information MDT Leads/Clinical Effectiveness Leads Jun Aug 3.2 Input to the production of Annual Audit Report. Audit reports issued in line with agreed schedule. Report contains clearly defined regional/local actions to address areas where performance requires to be improved and status of unresolved actions highlighted and escalated as Information /MCN Clinical Lead/ MCN Sept Sept 3.3 Identify requirements for further data analysis to aid understanding of variance, and inform improvement work. Improved understanding of reasons for variance, enabling more targeted improvement work to be undertaken, ensuring service issues are addressed. Lead/MCN Aug 3.4 Monitor progress against agreed local/regional action/improvement plans, ensuring regional actions identified are progressed and outcomes documented and reported. reported to the MCN Advisory Board. Lead/MCN / Board Clinical Effectiveness Leads Nov Ongoing Lung Cancer MCN Work Plan /18 v1.0 25/04/ 2

3 4. Update and further develop the regional service map for Lung Cancer service provision, detailing the points of service delivery and the connections between them. Lung Cancer service map updated to maintain a baseline position in support of use as an internal planning resource. s 4.1 Review the current high level service map for Lung Cancer MCN. Service map reviewed for Lung Cancer MCN. s / MDT Chairs Sep 4.2 Agree and source additional information to populate new service map template. Regionally agreed high level service map for Lung Cancer which will be used to inform any detailed service planning work undertaken. s / MDT Chairs Oct Feb 4.3 Finalise and publish service map for Lung cancer. Annual update of the Service map completed to maintain a baseline position and published on intranet site. Lead / MCN Feb 5. Utilise learning from the NHS Lanarkshire TCAT Lung Cancer Project to determine applicability of utilisation of HNA and treatment summaries within the WoS. In collaboration with key stakeholders, development of an implementation plan to support regional rollout. MCN 5.1 Assess the learning and outcomes from the NHS Lanarkshire TCAT project and clearly define the application of suitable components within the WoS. 5.2 Develop information, rollout, and local implementation tools, for use as by NHS Boards as required within the Lung Cancer MCN Work Plan /18 v1.0 25/04/ Clear information available on the model utilised in NHS Lanarkshire, with identification of those components that are transferrable within the region. Regional rollout through local NHS Board implementation. MCN Oct Sep 3

4 WoS. MCN 6. Review of diagnostic pathways to ensure they remain fit for purpose, are as efficient as possible in the scheduling of investigations, and ensure timely diagnosis and treatment of lung cancer patients. Efficient and timely diagnosis of lung cancer via an optimal pathway model. 6.1 Audit of cancer waiting times to determine whether areas in the pathway are potentially contributing to waiting times adjustments being applied. Identification of any specific areas within the diagnostic pathway where there are opportunities for improved efficiencies. MCN 6.2 Pilot project/test of change to be undertaken of an alternative order of diagnostic investigations for patients with suspected lung cancer. (NHS GGC & NHS Lanarkshire) Information on alternative pathways providing the opportunity for comparison, and identification of an optimal diagnostic model. MCN il 7. Further development and formalisation of the Malignant Pleural Mesothelioma (MPM) service both regionally and nationally. Robust regional and national service identifying areas of good practice and improvement opportunity. MCN 7.1 Development of performance measures for MPM, utilising the current national lung cancer dataset to identify appropriate fields for use and assess the scope of reporting. 7.2 Develop draft MPM performance indicators for engagement with all clinical specialities involved in the Lung Cancer MCN Work Plan /18 v1.0 25/04/ Full appraisal of the current national dataset and identification and understanding of the information that can be utilised in reporting performance against MPM. Draft performance indicators that have undergone wide discussion and engagement. / Information Team / Information Team June June Dec 4

5 management of patients with MPM across the region. 7.3 Prepare final MPM performance indicators for endorsement by members of the MCN and other approval bodies (RCCL, RCAG, Board Leads) as Fully endorsed MPM performance measures for implementation across the Region. Clinical Lead / Dec 7.4 Contribute to the development of the business case to develop a national MPM service/network. Regional input to the proposed national service. Clinical Lead / K Blyth / MCN Ongoing 8. Undertake targeted audit/review against the following areas of concern/interest noted in the 2015 QPI data analysis day mortality following palliative chemotherapy administration. 8.2 Completion of treatment rates in patients with Stage IIIB and IV NSCLC receiving doublet chemotherapy including platinum as their first line regiment numerator of QPI 11(ii). Further in-depth analysis to identify potential areas of improvement, or areas where changes in practice could be beneficial. TBD/Information Team day mortality in SCLC patients receiving chemotherapy + radiotherapy numerator of QPI 12(ii). Lung Cancer MCN Work Plan /18 v1.0 25/04/ 5